Osteoarthritis News and Research

Latest Osteoarthritis News and Research

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that a compound identified by the Company as an antagonist of GPR87, an orphan GPCR recently unlocked for drug development by Omeros and linked to squamous cell carcinoma, potentiates the tumor-killing activity of doxorubicin (Adriamycin), a widely used chemotherapeutic agent.

10 Nov 2010

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

Covidien, a leading global provider of healthcare products, announced the results of an analysis that will be presented at the American College of Rheumatology's Annual Scientific Meeting. A pooled analysis of safety data suggests that patients with knee osteoarthritis (OA) receiving the topical PENNSAID® (diclofenac sodium topical solution) 1.5% w/w had significantly fewer gastrointestinal (GI)-related adverse events than those receiving an oral non-steroidal anti-inflammatory drug (NSAID).

10 Nov 2010

Special Surgery investigators to present future of clinical care at ACR annual meeting

Hospital for Special Surgery physicians who focus on lupus, scleroderma and related conditions are traveling from New York City to Atlanta this week to share their recent findings at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR).

10 Nov 2010

Common foot disorders more prevalent among African Americans

Common foot disorders such as flat feet, corns and bunions are more prevalent among African Americans than in whites, a new study by University of North Carolina at Chapel Hill researchers has found.

10 Nov 2010

Ultrasound needle guidance improves performance and outcomes of knee injections

The use of ultrasound needle guidance improves the performance, outcomes and the cost-effectiveness of knee injections in people with osteoarthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

Interleukin Genetics receives two grants under QTDP program to advance obesity, osteoarthritis genetic research

Interleukin Genetics, Inc. today announced that on November 1, 2010 notification was received that it has been awarded two grants totaling $473,393 by the United States Government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the Company's genetic research projects related to obesity and osteoarthritis.

9 Nov 2010

Special mobility shoes benefit people with osteoarthritis

The use of special mobility shoes can help ease knee pain and slow disease progression in people with osteoarthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Tai Chi benefits individuals with arthritis

In the largest study to date of the Arthritis Foundation's Tai Chi program, participants showed improvement in pain, fatigue, stiffness and sense of well-being.

8 Nov 2010

FDA approves Cymbalta for treatment of chronic musculoskeletal pain

The U.S. Food and Drug Administration today approved Cymbalta (duloxetine hydrochloride) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain. Cymbalta was first used to treat major depressive disorder in 2004.

8 Nov 2010

Study finds vitamin D supplement does not reduce knee osteoarthritis progression

Adding vitamin D as a supplement does not appear to lessen the symptoms, or slow the progression, of knee osteoarthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that three of the Company's therapeutic development programs, VIMOVO (naproxen / esomeprazole magnesium) (formerly PN400), PA32540 and PA65020, qualified to receive federal grant funding under The Patient Protection and Affordable Care Act.

3 Nov 2010

FDA selects Rochester to lead initiative to identify improved pain treatments

Pain is the most common symptom leading patients to see a physician in the United States, yet the most widely prescribed medications - opioids and non-steroidal anti-inflammatory drugs (NSAIDS) - have major drawbacks, including the potential for misuse and abuse and adverse effects that limit long-term use. While scientists have made great strides in understanding the physical and chemical processes that occur when people feel pain, new treatments with improved safety and effectiveness are still needed for the more than 76 million Americans with acute and chronic pain.

2 Nov 2010

Physicians suggest patients who receive MoM hip replacement to pay attention on post-operative pain

Total hip arthroplasty (THA) is one of the most successful surgeries of the past several decades. This procedure has relieved pain and restored movement to hundreds of thousands of people. The decision to have hip replacement surgery should be only made after discussion between the patient and his or her orthopaedic surgeon.

30 Oct 2010

VIVUS receives FDA CRL for QNEXA NDA

VIVUS, Inc. announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.

29 Oct 2010

Metagenics awarded two new patents for hops-derived anti-inflammatory compositions

Metagenics, Inc. has been awarded two new patents for discoveries relating to its research on the anti-inflammatory properties of reduced iso-alpha acids (RIAA) derived from hops. Metagenics is a life sciences company focused on reversing chronic illness and improving health through therapeutic nutrition and lifestyle changes. The discoveries were made by researchers at Metagenics’ wholly-owned biotechnology subsidiary, MetaProteomics® LLC.

28 Oct 2010

POZEN reports net loss of $8.6M for third quarter 2010 vs. net income of $6.7M for third quarter 2009

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the third quarter ended September 30, 2010.

28 Oct 2010

Artimplant reports net loss of SEK 5.2 million for 2010 third quarter

Artimplant AB: Net revenue for the third quarter amounted to SEK 5.1 million (5.5) and for January-September SEK 14.9 million (18.2).

28 Oct 2010

Novartis informs Emisphere on First Interpretable Results of two-year Phase III Study 2301 in osteoarthritis

Emisphere Technologies, Inc. announced today that Novartis Pharma AG provided Emisphere with information regarding the First Interpretable Results of the two-year Phase III Study 2301 in osteoarthritis conducted by its license partner Nordic Bioscience with oral calcitonin (SMC021).

25 Oct 2010

Novartis releases study results on oral calcitonin for treatment of osteoarthritis: Unigene Laboratories

Unigene Laboratories, Inc. announced today that Novartis has released information on the first of two studies on oral calcitonin for the treatment of osteoarthritis conducted by its license partner Nordic Bioscience. The recently completed Study 2301, which assesses the safety and efficacy of oral calcitonin in the treatment of knee osteoarthritis, had three co-primary endpoints.

22 Oct 2010

Lubricin reduces wear to bone cartilage

A team of researchers in North Carolina has discovered that lubricin, a synovial fluid glycoprotein, reduces wear to bone cartilage. This result, which has implications for the treatment of sufferers of osteoarthritis, will be presented today at the AVS 57th International Symposium & Exhibition, taking place this week at the Albuquerque Convention Center in New Mexico.

21 Oct 2010

Osteoarthritis News and Research

Latest Osteoarthritis News and Research

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

Special Surgery investigators to present future of clinical care at ACR annual meeting

Common foot disorders more prevalent among African Americans

Ultrasound needle guidance improves performance and outcomes of knee injections

Interleukin Genetics receives two grants under QTDP program to advance obesity, osteoarthritis genetic research

Special mobility shoes benefit people with osteoarthritis

Tai Chi benefits individuals with arthritis

FDA approves Cymbalta for treatment of chronic musculoskeletal pain

Study finds vitamin D supplement does not reduce knee osteoarthritis progression

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

FDA selects Rochester to lead initiative to identify improved pain treatments

Physicians suggest patients who receive MoM hip replacement to pay attention on post-operative pain

VIVUS receives FDA CRL for QNEXA NDA

Metagenics awarded two new patents for hops-derived anti-inflammatory compositions

POZEN reports net loss of $8.6M for third quarter 2010 vs. net income of $6.7M for third quarter 2009

Artimplant reports net loss of SEK 5.2 million for 2010 third quarter

Novartis informs Emisphere on First Interpretable Results of two-year Phase III Study 2301 in osteoarthritis

Novartis releases study results on oral calcitonin for treatment of osteoarthritis: Unigene Laboratories

Lubricin reduces wear to bone cartilage

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Osteoarthritis News and Research

Latest Osteoarthritis News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in